Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495247 | 0.79 | CA12 (0.33) | CA12CA1CA2CA9NOTUM | |
| SCHEMBL28113418 | 0.73 | CA12 (0.38) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL30390241 | 0.69 | CA12 (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL30015392 | 0.68 | CYP2C19 (0.33) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL9464929 | 0.68 | NOS1 (0.38) | KDM4EALDH1A1MAPK1NOTUM | |
| SCHEMBL3985923 | 0.64 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL4821029 | 0.64 | — | — | |
| SCHEMBL1488644 | 0.64 | — | — | |
| SCHEMBL22831412 | 0.64 | — | — | |
| SCHEMBL10510430 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368623-A1 | PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES | GENETIC INTELLIGENCE INC (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368623-A1 | PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES | MYC, MYCBP, MKI67 | CA12 4514/4885CA1 4792/4885CA2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.